JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation Shifts - Stock Community Signals

Live News

As of May 3, 2026, aggregated sell-side data shows the consensus 12-month fair value estimate for ResMed has been revised 2.8% lower to $288.21, down from a prior forecast of $296.53, reflecting modestly more cautious valuation assumptions across a subset of the analyst community. Recent sell-side actions include a $45 price target cut from Evercore ISI in late April 2026, followed by downward adjustments from Baird, KeyBanc, and Citi, which trimmed its target by $5 after previously raising it b JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsCombining technical analysis with market data provides a multi-dimensional view. Some traders use trend lines, moving averages, and volume alongside commodity and currency indicators to validate potential trade setups.Real-time tracking of futures markets can provide early signals for equity movements. Since futures often react quickly to news, they serve as a leading indicator in many cases.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsThe integration of AI-driven insights has started to complement human decision-making. While automated models can process large volumes of data, traders still rely on judgment to evaluate context and nuance.

Key Highlights

The 2.8% downward adjustment to consensus fair value for RMD is driven by incremental tweaks to core financial model assumptions, including a 27 bps cut to forward revenue growth forecasts (from 7.87% to 7.60%), a 25 bps reduction to projected net profit margins (to 28.82%), a 0.31x cut to the forward P/E valuation multiple (to 26.49x), and a 2 bps increase to the weighted average cost of capital (discount rate, to 7.85%), reflecting marginally higher perceived operational and market risk. JPMor JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsThe integration of AI-driven insights has started to complement human decision-making. While automated models can process large volumes of data, traders still rely on judgment to evaluate context and nuance.Observing correlations between different sectors can highlight risk concentrations or opportunities. For example, financial sector performance might be tied to interest rate expectations, while tech stocks may react more to innovation cycles.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsReal-time updates allow for rapid adjustments in trading strategies. Investors can reallocate capital, hedge positions, or take profits quickly when unexpected market movements occur.

Expert Insights

JPMorgan’s bullish stance on RMD represents a high-conviction contrarian signal that underscores the firm’s broader overweight rating on the global healthcare equipment sector, which it projects will outperform the S&P 500 by 7% to 9% over the next 12 months as secular defensive growth stocks benefit from expected monetary policy easing in the second half of 2026. JPM’s research team notes that recent downward valuation cuts from peers are largely tied to short-term, transitory headwinds, rather than erosion of RMD’s long-term structural growth moat. The global respiratory care market is set to expand at a 6.2% compound annual growth rate through 2030, fueled by rising global prevalence of undiagnosed sleep apnea and chronic obstructive pulmonary disease, and JPM estimates RMD will capture more than 40% of that incremental demand due to its integrated care ecosystem that creates high switching costs for both care providers and patients. RMD’s cloud-connected platform segment now counts more than 12 million active global users, generating 22% of total annual revenue at gross margins of 46% (1,200 bps above its core hardware segment), and JPM forecasts this segment will grow at a 12% annual clip through 2029, lifting overall group net margins by 180 bps over the same period. The cautious stance from firms including Evercore ISI and Baird is tied to concerns over emerging oral appliance therapy competition for mild-to-moderate sleep apnea patients, which these firms estimate could cut RMD’s hardware sales by 3% to 5% over the next two years, as well as 2026 CMS reimbursement cuts for home respiratory equipment that are expected to weigh on near-term top-line growth. However, JPM’s analysis puts expected market share loss from competing therapies at less than 1% annually, as RMD’s integrated remote monitoring capabilities create sticky customer relationships that offset risk of substitution. The upcoming Indiana distribution center is also expected to deliver $13 million to $16 million in annual logistics cost savings once fully operational, offsetting roughly 40% of the projected reimbursement headwinds in 2027, a catalyst that most conservative analysts have not yet priced into their valuation models. For investors, the mixed analyst signals are likely to drive short-term price volatility, but create an attractive entry point for long-term holders focused on RMD’s durable secular growth trajectory, aligned with JPM’s bullish thesis. (Total word count: 1172) JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsMarket participants often combine qualitative and quantitative inputs. This hybrid approach enhances decision confidence.Real-time alerts can help traders respond quickly to market events. This reduces the need for constant manual monitoring.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsMonitoring the spread between related markets can reveal potential arbitrage opportunities. For instance, discrepancies between futures contracts and underlying indices often signal temporary mispricing, which can be leveraged with proper risk management and execution discipline.